HPV

9-Valent HPV Vaccine Shows Long-Term Effectiveness

The 9-valent human papillomavirus (HPV) vaccine (9vHPV), which has shown effectiveness against infections and disease related to HPV 31, 33, 45, 52, and 58, as well as non-inferior HPV 6, 11, 16, and 18 antibody responses compared with the quadrivalent HPV vaccine (qHPV), has shown long-term effectiveness, according to the results of a recent study.

While previous research has demonstrated the efficacy of the 9vHPV vaccine, its long-term efficacy is less well defined.  _______________________________________________________________________________________________________________________________________________________________________

RELATED CONTENT
HPV Vaccine: Questions and Controversies
HPV Vaccination Rates Still Low, Despite Increases
_______________________________________________________________________________________________________________________________________________________________________
 
In a randomized, double-blind, efficacy, immunogenicity, and safety study of the 9vHPV vaccine, researchers examined data from 105 study sites in 18 countries, including 14,215 women, aged 16 to 26 years, who received either the 9vHPV or qHPV vaccine. Participants had no previous abnormal cervical biopsy results or cervical cytology. Primary outcomes included high-grade cervical disease, vulvar disease, and vaginal disease related to HPV 31, 33, 45, 52, and 58, as well as non-inferiority of anti-HPV 6, 11, 16, and 18 geometric mean titres.

Overall, the incidence of high-grade disease was 0.5 cases per 10,000 person-years in the 9vHPV group and 19.0 cases per 10,000 person-years in the qHPV group, which represented a 97.4% efficacy. Between 1 month and 3 years after vaccination, HPV 6, 11, 16, and 18 geometric mean titres in the 9vHPV group were non-inferior to the qHPV group.

“The 9vHPV vaccine could potentially provide broader coverage and prevent 90% of cervical cancer cases worldwide,” the researchers concluded.

—Michael Potts

Reference:

Huh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial [published online September 5, 2017]. Lancet. doi: http://dx.doi.org/10.1016/S0140-6736(17)31821-4.